Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Strides Pharma Science Ltd (BOM:532531) posts strong Q1 FY27 results with 17% ex-US growth and 57% PAT jump, while navigating US market softness and geopolitical headwinds.
Strides Pharma Science Ltd (BOM:532531) reports robust revenue growth and strategic investments, despite challenges in the US market.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.